From osteoarthritis treatments to future regenerative therapies for cartilage

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 913-925

  Clouet, Johann ^a,b   Vinatier, Claire ^a,c   Merceron, Christophe ^a   Pot vaucel, Marianne ^b   Maugars, Yves ^b   Weiss, Pierre ^a   Grimandi, Gaël ^a,b   Guicheux, Jérôme ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c GRAFTYS SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BICIFADINE; CALCITONIN; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFIPLADIB; FIBROBLAST GROWTH FACTOR 18; GLUCOCORTICOID; GLUCOSAMINE; HYALURONIC ACID; ICATIBANT; IDEA 033; INFLIXIMAB; LICOFELONE; MATRIX METALLOPROTEINASE INHIBITOR; NAPROXCINOD; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PIASCLEDINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; S ADENOSYLMETHIONINE; SD 6010; TISSUE SCAFFOLD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHRODESIS; ARTHROPLASTY; ARTICULAR CARTILAGE; BIOMECHANICS; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL CULTURE; CELL THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CROHN DISEASE; CYTOKINE PRODUCTION; DEBRIDEMENT; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GENE THERAPY; GENETIC POLYMORPHISM; HIP OSTEOARTHRITIS; HUMAN; INFLAMMATION; INJECTION SITE INFECTION; INJECTION SITE PAIN; KNEE OSTEOARTHRITIS; LIVER TOXICITY; MOLECULAR BIOLOGY; MUSCLE TRAINING; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OSTEOTOMY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STEM CELL TRANSPLANTATION; SYNOVITIS; SYNOVIUM; TISSUE ENGINEERING; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT INDICATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRODESIS; ARTHROPLASTY, REPLACEMENT; CARTILAGE, ARTICULAR; CELL TRANSPLANTATION; GENE THERAPY; HUMANS; ORTHOPEDIC PROCEDURES; OSTEOARTHRITIS; OSTEOTOMY; REGENERATION; TISSUE ENGINEERING; TREATMENT OUTCOME;

EID: 70349466527     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.012     Document Type: Review

References (114)

1. Cats-Baril W.L., and Frymoyer J.W. Demographic factors associated with the prevalence of disability in the general population. Analysis of the NHANES I database. Spine 16 (1991) 671-674
2. Felson D.T. Obesity and vocational and avocational overload of the joint as risk factors for osteoarthritis. J. Rheumatol. Suppl. 70 (2004) 2-5
3. Aigner T., et al. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv. Drug Deliv. Rev. 58 (2006) 128-149
4. Roach H.I., et al. Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. Curr. Drug Targets 8 (2007) 271-282
5. Chang J., and Poole C.A. Sequestration of type VI collagen in the pericellular microenvironment of adult chrondrocytes cultured in agarose. Osteoarthritis Cartilage 4 (1996) 275-285
6. Aigner T., and Stove J. Collagens - major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair. Adv. Drug Deliv. Rev. 55 (2003) 1569-1593
7. Dieppe P., and Kirwan J. The localization of osteoarthritis. Br. J. Rheumatol. 33 (1994) 201-203
8. Aigner T., et al. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum. 42 (1999) 1443-1450
9. Wollheim F.A. Early stages of osteoarthritis: the search for sensitive predictors. Ann. Rheum. Dis. 62 (2003) 1031-1032
10. Lippiello L., et al. Collagen synthesis in normal and osteoarthritic human cartilage. J. Clin. Invest. 59 (1977) 593-600
11. Kim H.A., and Blanco F.J. Cell death and apoptosis in osteoarthritic cartilage. Curr. Drug Targets 8 (2007) 333-345
12. Abramson S.B. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res. Ther. 10 Suppl. 2 (2008) S2
13. Loeser Jr. R.F. Aging cartilage and osteoarthritis - what's the link?. Sci. Aging Knowledge Environ. 2004 (2004) pe31
14. Goldring M.B., and Goldring S.R. Osteoarthritis. J. Cell Physiol. 213 (2007) 626-634
15. Burrage P.S., and Brinckerhoff C.E. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr. Drug Targets 8 (2007) 293-303
16. Berenbaum F., and Sellam J. Obesity and osteoarthritis: what are the links?. Joint Bone Spine 75 (2008) 667-668
17. Toussirot E., et al. The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr. Med. Chem. 14 (2007) 1095-1100
18. Lane N.E., et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum. 54 (2006) 1246-1254
19. Wu Q., et al. Overexpression of Smurf2 stimulates endochondral ossification through upregulation of beta-catenin. J. Bone Miner. Res. 23 (2008) 552-563
20. Krasnokutsky S., et al. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 16 Suppl. 3 (2008) S1-S3
21. Benito M.J., et al. Synovial tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 64 (2005) 1263-1267
22. Goldring S.R., and Goldring M.B. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin. Orthop. Relat. Res. 427 Suppl. (2004) S27-36
23. Lajeunesse D. The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage 12 Suppl. A (2004) S34-S38
24. Martel-Pelletier J., et al. New thoughts on the pathophysiology of osteoarthritis: one more step toward new therapeutic targets. Curr. Rheumatol. Rep. 8 (2006) 30-36
25. Martel-Pelletier J., and Pelletier J.P. New insights into the major pathophysiological processes responsible for the development of osteoarthritis. Semin. Arthritis Rheum. 34 6 Suppl. 2 (2005) 6-8
26. Gerwin N., et al. Intraarticular drug delivery in osteoarthritis. Adv. Drug Deliv. Rev. 58 (2006) 226-242
27. van der Kraan P.M., and van den Berg W.B. Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing. Ageing Res. Rev. 7 (2008) 106-113
28. Ikegawa S. Genomic approaches to bone and joint diseases. Current status of genetic study of osteoarthritis. Clin. Calcium 18 (2008) 162-167
29. Gegout P.P., et al. Adipokines in osteoarthritis: friends or foes of cartilage homeostasis?. Joint Bone Spine 75 (2008) 669-671
30. ACR. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 43 (2000) 1905-1915
31. Zhang W., et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 66 (2007) 377-388
32. Zhang W., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16 (2008) 137-162
33. Zhang W., et al. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 63 (2004) 901-907
34. Towheed T., et al. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst. Rev. (2000) CD000517
35. Glass G.G. Osteoarthritis. Dis. Mon. 52 (2006) 343-362
36. Ayral X. Injections in the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. 15 (2001) 609-626
37. Derfoul A., et al. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage 15 (2007) 646-655
38. Pavelka K., et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 162 (2002) 2113-2123
39. Tiraloche G., et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 52 (2005) 1118-1128
40. McAlindon T.E., et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283 (2000) 1469-1475
41. Clegg D.O., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354 (2006) 795-808
42. Najm W.I., et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet. Disord. 5 (2004) 6
43. Soeken K.L., et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J. Fam. Pract. 51 (2002) 425-430
44. Marshall K.W. Viscosupplementation for osteoarthritis: current status, unresolved issues, and future directions. J. Rheumatol. 25 (1998) 2056-2058
45. Wang C.T., et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J. Bone Joint Surg. Am. 86-A (2004) 538-545
46. Simon T.M., and Jackson D.W. Articular cartilage: injury pathways and treatment options. Sports Med. Arthrosc. 14 (2006) 146-154
47. Steinmeyer J., and Konttinen Y.T. Oral treatment options for degenerative joint disease - presence and future. Adv. Drug Deliv. Rev. 58 (2006) 168-211
48. Qvist P., et al. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?. Pharmacol. Res. 58 (2008) 1-7
49. Pelletier J.P., and Martel-Pelletier J. DMOAD developments: present and future. Bull NYU Hosp. Jt. Dis. 65 (2007) 242-248
50. Bissett D., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 842-849
51. Chevalier X., et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32 (2005) 1317-1323
52. Magnano M.D., et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J. Rheumatol. 34 (2007) 1323-1327
53. Karsdal M.A., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 16 (2008) 638-646
54. Garnero P., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16 (2008) 660-666
55. El Hajjaji H., et al. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 904-911
56. Pelletier J.P., et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 34 (2004) 527-538
57. Tat S.K., et al. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?. Keio J. Med. 58 (2009) 29-40
58. Hayashi M., et al. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res. Ther. 10 (2008) R118
59. Moore E.E., et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13 (2005) 623-631
60. Hunziker E.B. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 10 (2002) 432-463
61. Ethgen O., et al. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J. Bone Joint Surg. Am. 86-A (2004) 963-974
62. Deirmengian C.A., and Lonner J.H. What's new in adult reconstructive knee surgery. J. Bone Joint Surg. Am. 90 (2008) 2556-2565
63. Gidwani S., and Fairbank A. The orthopaedic approach to managing osteoarthritis of the knee. Br. Med. J. 329 (2004) 1220-1224
64. Curl W.W., et al. Cartilage injuries: a review of 31,516 knee arthroscopies. Arthroscopy 13 (1997) 456-460
65. Fritz J., et al. Articular cartilage defects in the knee - basics, therapies and results. Injury 39 Suppl. 1 (2008) S50-S57
66. Hunziker E.B., and Kapfinger E. Removal of proteoglycans from the surface of defects in articular cartilage transiently enhances coverage by repair cells. J. Bone Joint Surg. Br. 80 (1998) 144-150
67. Livesley P.J., et al. Arthroscopic lavage of osteoarthritic knees. J. Bone Joint Surg. Br. 73 (1991) 922-926
68. Gibson J.N., et al. Arthroscopic lavage and debridement for osteoarthritis of the knee. J. Bone Joint Surg. Br. 74 (1992) 534-537
69. Ogilvie-Harris D.J., and Jackson R.W. The arthroscopic treatment of chondromalacia patellae. J. Bone Joint Surg. Br. 66 (1984) 660-665
70. Rangger C., et al. Osteoarthritis after arthroscopic partial meniscectomy. Am. J. Sports Med. 23 (1995) 240-244
71. Buckwalter J.A., and Brown T.D. Joint injury, repair, and remodeling: roles in post-traumatic osteoarthritis. Clin. Orthop. Relat. Res. 423 (2004) 7-16
72. Steinwachs M.R., et al. Marrow stimulation techniques. Injury 39 Suppl. 1 (2008) S26-S31
73. Steadman J.R., et al. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. J. Knee Surg. 15 (2002) 170-176
74. Garrett J.C. Osteochondral allografts for reconstruction of articular defects of the knee. Instr. Course Lect. 47 (1998) 517-522
75. Lane J.M., et al. Joint resurfacing in the rabbit using an autologous osteochondral graft. J. Bone Joint Surg. Am. 59 (1977) 218-222
76. Outerbridge H.K., et al. The use of lateral patellar autologous grafts for the repair of large osteochondral defects in the knee. Acta Orthop. Belg. 65 Suppl. 1 (1999) 129-135
77. Hangody L., et al. Arthroscopic autogenous osteochondral mosaicplasty for the treatment of femoral condylar articular defects. A preliminary report. Knee Surg. Sports Traumatol. Arthrosc. 5 (1997) 262-267
78. Hangody L., et al. Autologous osteochondral grafting - technique and long-term results. Injury 39 Suppl. 1 (2008) S32-S39
79. Brittberg M., et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331 (1994) 889-895
80. Hittinger, M.C. (2005) Autologous chondrocyte implantation in the knee joint. Report of the French National Authority for Health. p. 54
81. Bachmann G., et al. MRI in the follow-up of matrix-supported autologous chondrocyte transplantation (MACI) and microfracture. Radiologe 44 (2004) 773-782
82. Schnabel M., et al. Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage 10 (2002) 62-70
83. Peterson L., et al. Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin. Orthop. Relat. Res. 374 (2000) 212-234
84. Elisseeff J. Injectable cartilage tissue engineering. Expert Opin. Biol. Ther. 4 (2004) 1849-1859
85. Nesic D., et al. Cartilage tissue engineering for degenerative joint disease. Adv. Drug Deliv. Rev. 58 (2006) 300-322
86. Langer R., and Vacanti J.P. Tissue engineering. Science 260 (1993) 920-926
87. Merceron C., et al. Adipose-derived mesenchymal stem cells and biomaterials for cartilage tissue engineering. Joint Bone Spine 75 (2008) 672-674
88. Ateshian G.A. Artificial cartilage: weaving in three dimensions. Nat. Mater. 6 (2007) 89-90
89. Drury J.L., and Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 24 (2003) 4337-4351
90. Sontjens S.H., et al. Biodendrimer-based hydrogel scaffolds for cartilage tissue repair. Biomacromolecules 7 (2006) 310-316
91. Vinatier C., et al. Engineering cartilage with human nasal chondrocytes and a silanized hydroxypropyl methylcellulose hydrogel. J. Biomed. Mater. Res. A 80 (2007) 66-74
92. Vinatier C., et al. Nasal chondrocytes and fibrin sealant for cartilage tissue engineering. J. Biomed. Mater. Res. A 89 (2009) 176-185
93. Vinatier C., et al. Cartilage and bone tissue engineering using hydrogels. Biomed. Mater. Eng. 16 4 Suppl. (2006) S107-S113
94. Isogai N., et al. Comparison of different chondrocytes for use in tissue engineering of cartilage model structures. Tissue Eng. 12 (2006) 691-703
95. Malda J., et al. Expansion of bovine chondrocytes on microcarriers enhances redifferentiation. Tissue Eng. 9 (2003) 939-948
96. Magne D., et al. Mesenchymal stem cell therapy to rebuild cartilage. Trends Mol. Med. 11 (2005) 519-526
97. Pittenger M.F., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
98. Liu T.M., et al. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 25 (2007) 750-760
99. Awad H.A., et al. Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin scaffolds. Biomaterials 25 (2004) 3211-3222
100. Fraser J.K., et al. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 24 (2006) 150-154
101. Puissant B., et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 129 (2005) 118-129
102. Jin C.Z., et al. Human amniotic membrane as a delivery matrix for articular cartilage repair. Tissue Eng. 13 (2007) 693-702
103. Poole C.A. Articular cartilage chondrons: form, function and failure. J. Anat. 191 Pt 1 (1997) 1-13
104. Bueno E.M., et al. Wavy-walled bioreactor supports increased cell proliferation and matrix deposition in engineered cartilage constructs. Tissue Eng. 11 (2005) 1699-1709
105. Arokoski J.P., et al. Normal and pathological adaptations of articular cartilage to joint loading. Scand. J. Med. Sci. Sports 10 (2000) 186-198
106. Mauck R.L., et al. Functional tissue engineering of articular cartilage through dynamic loading of chondrocyte-seeded agarose gels. J. Biomech. Eng. 122 (2000) 252-260
107. Guilak F., et al. The role of biomechanics and inflammation in cartilage injury and repair. Clin. Orthop. Relat. Res. 423 (2004) 17-26
108. de Crombrugghe B., et al. Regulatory mechanisms in the pathways of cartilage and bone formation. Curr. Opin. Cell Biol. 13 (2001) 721-727
109. Hirao M., et al. Oxygen tension regulates chondrocyte differentiation and function during endochondral ossification. J. Biol. Chem. 281 (2006) 31079-31092
110. Malladi P., et al. Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am. J. Physiol. Cell Physiol. 290 (2006) C1139-C1146
111. Schipani E., et al. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 15 (2001) 2865-2876
112. Saraf A., and Mikos A.G. Gene delivery strategies for cartilage tissue engineering. Adv. Drug Deliv. Rev. 58 (2006) 592-603
113. Di Cesare P.E., et al. Regional gene therapy for full-thickness articular cartilage lesions using naked DNA with a collagen matrix. J. Orthop. Res. 24 (2006) 1118-1127
114. Park J., et al. Transgene-activated mesenchymal cells for articular cartilage repair: a comparison of primary bone marrow-, perichondrium/periosteum- and fat-derived cells. J. Gene Med. 8 (2006) 112-125